Stem cells and cancer immunotherapy: Arrowhead’s 2nd annual cancer immunotherapy conference

Journal for ImmunoTherapy of Cancer

John Yu^1,11  Lili Yang^1,10  Albert J Wong⁶  Raul Vizcardo^1,13  David M Spencer⁷  Nicholas P Restifo⁸  Daniel J Powell Jr^1,14  Claudia M Palena⁸  Richard A Morgan⁸  William Matsui⁹  Masoud H Manjili^1,15  Richard C Koya⁵  Elaine Hurt²  Philip D Greenberg^1,16  Kenneth Geles^1,12  Soldano Ferrone³  Brian J Czerniecki^1,14  Andrew Cornforth⁴  Maurizio Chiriva-Internati^1,17  Adrian Bot¹ 

[1] Kite Pharma Inc., 2225 Colorado Avenue, Santa Monica, CA 90404, USA;MedImmune, Gaithersburg, MD, USA;Harvard Medical School, BostonMA, USA;California Stem Cell, Inc., Irvine, CA, USA;Roswell Park Cancer Institute, Buffalo, NY, USA;Stanford University Medical Center, Stanford, CA, USA;Bellicum Pharmaceuticals, Inc, Houston, TX, USA;National Cancer Institute, Bethesda, MD, USA;Johns Hopkins University School of Medicine, Baltimore, MD, USA;University of California, Los Angeles, CA, USA;Immunocellular Therapeutics, Calabasas, CA, USA;Pfizer Inc., New york, NY, USA;RIKEN Research Center for Allergy and Immunology, Yokohama, Japan;University of Pennsylvania, Philadelphia, PA, USA;Virginia Commonwealth University School of Medicine, Massey Cancer Center, Richmond, VA, USA;Fred Hutchinson Cancer Research Center, Seattle, WA, USA;Texas Tech University of Health Sciences Center School of Medicine, Lubbock, TX, USA

关键词: Vaccines;    Antibodies;    Adoptive T cell therapy;    Hematopoietic stem cells;    Cancer stem cells;    Immunotherapy;   

Others  :  812428
DOI  :  10.1186/2051-1426-2-6

 received in 2013-12-26, accepted in 2014-03-12,  发布年份 2014

【 摘 要 】

Investigators from academia and industry gathered on April 4 and 5, 2013, in Washington DC at the Arrowhead’s 2^nd Annual Cancer Immunotherapy Conference. Two complementary concepts were discussed: cancer “stem cells” as targets and therapeutic platforms based on stem cells.

【 授权许可】

   
2014 Bot et al.; licensee BioMed Central Ltd.